The major brands in China’s urinalysis market are URIT, DIRUI, AVE, etc. URIT produced China’s first urine analyzer in 1984. And after nearly 40 years’ strenuous cultivation, it pioneered the modular urine analysis workflow using deep learning artificial intelligence (AI) image recognition technology.

Stay up-to-date with the latest happenings in the rapidly evolving field of In Vitro Diagnostics (IVD) in China.

South Korean diagnostics company Seegene on Wednesday reported a nearly 11 percent year-over-year increase in its second quarter revenues amid higher sales of its infectious disease testing reagents and PCR equipment in Europe and North America.

Twist Bioscience and SomaLogic announced on Wednesday a partnership to discover novel therapeutic targets and antibodies.

Illumina, Inc. today announced that it disagrees with, and will oppose, the U.S. Federal Trade Commission (FTC)’s challenge to its previously announced acquisition of GRAIL, a pre-commercial company founded to accelerate early screening of cancer.

The Precede consortium and Konica Minolta Precision Medicine said Tuesday that KMPM and its subsidiaries, Ambry Genetics and Invicro, have partnered with the international effort to advance diagnostic and screening approaches for pancreatic cancer early detection.

Tempus said on Tuesday that it has submitted a premarket approval application for its next-generation sequencing-based xT-Onco tumor profiling assay to the US Food and Drug Administration.

As one of the top local in vitro diagnostic companies, Autobio will actively carry out a variety of strategic cooperation in 2021.

On August 16, 2021,Sino Biological Inc. successfully listed on the Growth Enterprise Market of Shenzhen Stock Exchange. Sino Biological publicly issued 17 million shares and raised 4.98 billion yuan. The issue price is RMB 292.92 per share. The opening rose 104.8% to 599.90 yuan per share.

Clarified Precision Medicine on Friday said that it has completed its acquisition of molecular diagnostics firm Interpares Biomedicine.

Biocept reported after the close of the market on Monday that its second quarter revenues increased dramatically year over year, as the cancer diagnostics firm continued its provision of COVID-19 testing.

Yesterday, Orient Gene issued a report, announcing that the company has successfully completed the acquisition of 100% of Beijing Shouyi Biochem. This acquisition is intended to structure the domestic market and extend product lines of in vitro diagnostics.